Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

20119,326 citationsJournal Articlebronze Open Access

Authors

Manesh R. Patel · Clinical Research Institute

Kenneth W. Mahaffey · Duke Medical Center

Jyotsna Garg · Duke Medical Center

Guohua Pan · Johnson & Johnson (United States)

Daniel E. Singer · Massachusetts General Hospital

Werner Hacke · Heidelberg University

Günter Breithardt ·

Abstract

In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism. There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group. (Funded by Johnson & Johnson and Bayer; ROCKET AF ClinicalTrials.gov number, NCT00403767.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Cardiac Arrhythmias and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 365, Issue 10, pp. 883-891

DOI: 10.1056/nejmoa1009638

Field-Weighted Citation Impact: 436.73